Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…Abstract Number: 1953 • 2015 ACR/ARHP Annual Meeting
Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis that primarily affects the aorta and external carotid arteries and their branches, leading to ischemic manifestations…Abstract Number: 2159 • 2015 ACR/ARHP Annual Meeting
Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)
Background/Purpose: While many manifestations of TA improve quickly after starting glucocorticoid therapy, vascular inflammation appears to persist. To obtain more information about the duration of…Abstract Number: 1954 • 2015 ACR/ARHP Annual Meeting
How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis?
Background/Purpose: Giant cell arteritis (GCA), the most common primary vasculitis, can cause irreversible blindness in 20-30% of untreated cases, but glucocorticoid therapy leads to significant…Abstract Number: 2161 • 2015 ACR/ARHP Annual Meeting
Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids. Many patients require chronic steroid therapy with associated significant side effects. There is a…Abstract Number: 1958 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasonography-Derived Signs in Giant Cell Arteritis: Literature Review and Meta-Analysis
Background/Purpose: Giant Cell Arteritis (GCA) is the most common form of systemic inflammatory vasculitis in elderly people, with prevalence still increasing, and for which there…Abstract Number: 1960 • 2015 ACR/ARHP Annual Meeting
a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis
Background/Purpose: There is an increased use of vascular ultrasound (US) for diagnosing giant cell arteritis (GCA). Consequently, extensive and structured training of ultrasonographers performing vascular…Abstract Number: 1962 • 2015 ACR/ARHP Annual Meeting
Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis
Background/Purpose: Ultrasound is emerging as an alternative test to performing a temporal artery biopsy in the diagnosis of giant cell arteritis (GCA). Little is known…Abstract Number: 2786 • 2014 ACR/ARHP Annual Meeting
Aortitis: Outcomes from a Cohort of 196 Patients
Background/Purpose: Idiopathic aortitis is a rare diagnosis that may occur in the context of a primary systemic vasculitis, as part of a systemic autoimmune disease,…Abstract Number: 780 • 2014 ACR/ARHP Annual Meeting
Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis
Background/Purpose �:The mechanisms of the blood vessel injury in giant cell arteritis (GCA), a systemic vasculitis characterized by inflammation of large- and medium-sized vessels, remain…Abstract Number: 2770 • 2014 ACR/ARHP Annual Meeting
Polymyalgia Rheumatica Relapse and “Silence” Large Vessel Vasculitis. Is There Any Association?
Background/Purpose Large Vessel Vasculitis (LVV) can present with heterogeneous clinical manifestations, which range from general symptoms (fever, loss of weight) to the classic symptoms of …Abstract Number: 776 • 2014 ACR/ARHP Annual Meeting
A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA
Background/Purpose: IL-33, through binding to its receptor ST2 (suppression of tumorigenicity 2), encoded by the interleukin 1 receptor-like 1 (IL1RL1) gene, activates mast cells and…Abstract Number: 1956 • 2014 ACR/ARHP Annual Meeting
Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica
Background/Purpose: The role of B cells in auto-immunity may extend beyond the production of auto-antibodies. B cells can influence T cell responses via antigen presentation…Abstract Number: 775 • 2014 ACR/ARHP Annual Meeting
HLA-DRB1 Alleles in Susceptibility to Giant Cell Arteritis: Literature Review and Meta-Analysis
Background/Purpose Giant cell arteritis (GCA) has been reported by many studies (but not all) to be associated with carriage of HLA-DRB1*04, with variable results relating to…Abstract Number: 884 • 2014 ACR/ARHP Annual Meeting
Interleukin 6 Does Not Upregulate Pro Inflammatory Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis
Background/Purpose Interleukin 6 (IL 6) is postulated to play a role in the pathogenesis of Giant Cell Arteritis. Several studies have demonstrated increased circulating IL…
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- 36
- Next Page »